# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price t...
The room temperature approval applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well...
Piper Sandler analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $9 ...
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price targe...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and maintains $6 price...